Citigroup Issues Pessimistic Forecast for Phibro Animal Health (NASDAQ:PAHC) Stock Price

Phibro Animal Health (NASDAQ:PAHC) had its target price dropped by equities research analysts at Citigroup from $62.00 to $44.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Citigroup’s target price points to a potential upside of 20.60% from the stock’s current price.

PAHC has been the subject of a number of other research reports. Morgan Stanley set a $49.00 target price on Phibro Animal Health in a report on Friday, February 6th. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Weiss Ratings cut shares of Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 8th. Finally, Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $38.80.

Phibro Animal Health Stock Performance

PAHC traded up $1.23 during trading on Thursday, reaching $36.49. The company’s stock had a trading volume of 334,217 shares, compared to its average volume of 307,043. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17. The company’s fifty day moving average price is $52.53 and its 200-day moving average price is $46.40. Phibro Animal Health has a 52-week low of $22.51 and a 52-week high of $60.08. The company has a market capitalization of $1.48 billion, a price-to-earnings ratio of 15.62, a price-to-earnings-growth ratio of 0.56 and a beta of 0.61.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The business had revenue of $383.54 million during the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, equities analysts forecast that Phibro Animal Health will post 3.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Jack Bendheim sold 4,528 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $48.49, for a total value of $219,562.72. Following the completion of the transaction, the chief executive officer owned 56,152 shares in the company, valued at $2,722,810.48. This trade represents a 7.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 110,128 shares of company stock valued at $5,846,828 over the last quarter. 50.13% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Phibro Animal Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PAHC. Penserra Capital Management LLC purchased a new position in Phibro Animal Health in the 3rd quarter valued at about $519,000. JPMorgan Chase & Co. boosted its stake in shares of Phibro Animal Health by 1,730.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock worth $9,634,000 after purchasing an additional 225,110 shares during the last quarter. Citigroup Inc. grew its holdings in shares of Phibro Animal Health by 112.3% during the third quarter. Citigroup Inc. now owns 54,941 shares of the company’s stock worth $2,223,000 after buying an additional 29,066 shares in the last quarter. Advisors Preferred LLC acquired a new position in shares of Phibro Animal Health in the third quarter valued at approximately $3,953,000. Finally, Public Sector Pension Investment Board raised its position in shares of Phibro Animal Health by 14.7% in the third quarter. Public Sector Pension Investment Board now owns 79,478 shares of the company’s stock valued at $3,216,000 after buying an additional 10,184 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.